Ahead Therapeutics, member of CataloniaBio & HealthTech, has closed a funding round of 1,3 million euros through the microfinancing platform Capital Cell, also members.  

In the operation, current partners have also participated. Among them, Alfons Hidalgo, founder of Infinitec, stands out. Ahead Therapeutics, a spinoff of the Germans Trias i Pujol Research Institute, develops drugs for the treatment of autoimmune diseases. 

The start-up led by Martí Dalmases will use the funds to pass preclinical tests and advance to the first studies with human beings with its first candidate product. The company aims to validate its technological platform designed to treat and cure autoimmune diseases such as type 1 diabetes, celiac disease, multiple sclerosis, or rheumatoid arthritis, along with other diseases considered rare, which currently have no cure. 

The company is already at the next stage: raising a Series A round for a total of 10 million euros. Currently, the company is in the process of due diligence and in advanced negotiations with various funds specialized in the sector.